Eli Lilly and Company

The transcript does not provide any explicit information regarding current or future fundraising through debt or equity. Specific mentions on financial updates highlight: - Updated revenue guidance and investment in supply and demand generation activities. - Expectations for production increases (more saleable doses) to support continued growth. - References to operating margin ratios and investments in SG&A and R&D. - No direct comments or plans on issuing new debt or equity financing. Thus, there is no stated plan or announcement of fundraising via debt or equity in the provided transcript excerpts.

- Lilly plans to continue scaling R&D and step up investments across manufacturing and commercial to support successful launches of new medicines, including Mounjaro, Jaypirca, Zepbound, Kisunla, and Ebglyss. - The company has massively invested in parenteral filling capacity and API (Active Pharmaceutical Ingredient) capacity, with delivery timelines of 2 to 4 years. - Supply capacity efforts are progressing well, with strong growth expected in 2025 as announced capacities from prior years come online fully. - Lilly is increasing investments in SG&A and R&D to support pipeline advancement and demand generation activities. - The company is focused on expanding supply and demand in alignment, especially for products like Mounjaro and Zepbound. - They continue to invest in improved access infrastructure, including adding Medicaid coverage in multiple states and preparing for potential new indications like obstructive sleep apnea.

- Lilly expects strong revenue growth driven by new products such as Mounjaro and Zepbound, with over $3 billion growth in new product revenue in Q3 2024. - U.S. sequential quarter-over-quarter prescriptions for both Mounjaro and Zepbound remain strong and growing, supported by expanded access and supply. - The company targets at least 50% growth in Mounjaro sales for Q4 2024, with continued acceleration into 2025, supported by demand generation investments. - Global launches outside the U.S. (e.g., Europe, China, Japan) for Mounjaro contribute to volume growth. - Operating margin expansion is expected short-term due to ramping investments in SG&A and R&D, with sustained growth over the long term justified by these investments. - Supply capacity is increasing to meet growing demand, enabling Lilly to scale up shipments and reduce supply constraints experienced earlier in 2024. - The company anticipates ongoing market share growth in oncology and immunology segments alongside incretin products.

- Eli Lilly expects continued strong growth driven by new products such as Mounjaro, Zepbound, Jaypirca, Kisunla, and Ebglyss. - Revenue grew 42% in Q3 2024 (excluding divested olanzapine portfolio). - EPS in Q3 2024 was $1.19, up from $0.10 in Q3 2023, including a negative impact from acquired IPR&D charges. - Operating margin is expected to expand in the short term as investments in SG&A and R&D ramp up. - Long-term operating margin expansion is anticipated, justified by sustained investments in commercial and R&D activities. - Fourth-quarter 2024 growth expectations include approximately 50% revenue growth, with continued acceleration in demand generation. - Demand and supply are expected to converge in 2025, with ramped-up commercial activities and manufacturing capacity supporting this growth. - Lilly aims to sustain profitable growth through pipeline advancements, manufacturing investments, and expanded market access.

The transcript pages provided do not explicitly disclose specific details about current or expected orderbook or pending orders for Eli Lilly. However, relevant insights related to demand, supply, and market dynamics include: - Demand for Mounjaro and Zepbound is very strong, with more than 25% sequential quarter-over-quarter growth. - Supply constraints faced in the first half of 2025 have substantially improved, enabling increased demand generation efforts starting mid-November 2025. - Channel stocking showed lumpiness with restocking in Q2 followed by drawdown in Q3, but overall consumption is accelerating. - International launches continue to be rolled out, although timing was staggered to ensure supply reliability. - Commercial access for Mounjaro stands at 93%, with Zepbound near 90%, and progress continues in Medicaid access. - Supply capacity is ramping up with planned strong growth expected for 2025. - Operating margins aim to expand sustainably while supporting increased SG&A and R&D investments to drive growth. No direct numbers on orderbook/pending orders are disclosed.